Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Phosphoinositides and PIPs

Phosphoinositides and PIPs

Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Peripheral Artery Disease I: Introduction

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Management of spontaneous coronary artery dissection: Trends over time.

Vascular medicine (London, England)·2023

Same author

Stent-Based Gene Delivery for Coronary Disease.

Methods in molecular biology (Clifton, N.J.)·2022

Same author

Impact of supervised exercise on skeletal muscle blood flow and vascular function measured with MRI in patients with peripheral artery disease.

American journal of physiology. Heart and circulatory physiology·2022

Same author

Stent-based delivery of AAV2 vectors encoding oxidation-resistant apoA1.

Scientific reports·2022

Same author

Impact Of Cirrhosis On 90-Day Outcomes After Percutaneous Coronary Intervention (from A Nationwide Database).

The American journal of cardiology·2020

Same author

One-Year Outcomes of Percutaneous Coronary Intervention in Patients with End-Stage Liver Disease.

Clinical Medicine Insights. Cardiology·2020

Search research articles

Related Experiment Video

Updated: Jun 13, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA₂

Published on: September 26, 2025

Recent developments with lipoprotein-associated phospholipase A2 inhibitors.

Ryan J Chauffe¹, Robert L Wilensky, Emile R Mohler

¹Pennsylvania Hospital, 1 Pine West, 800 Spruce Street, Philadelphia, PA 19107, USA. chauffer@uphs.upenn.edu

Current Atherosclerosis Reports

|April 29, 2010

Summary

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) promotes atherosclerosis by generating inflammatory mediators. Inhibiting Lp-PLA(2) shows therapeutic potential by reducing plaque development and vulnerability.

More Related Videos

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Related Experiment Videos

Last Updated: Jun 13, 2026

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA2

A Liposome Membrane Permeability Assay for Investigating the Effects of Phosphatidylinositol Phosphate Groups on Membranotropic Action of Venom PLA₂

Published on: September 26, 2025

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

High-Density Lipoprotein-Specific Phospholipid Efflux Assay

Published on: September 30, 2025

Area of Science:

Cardiovascular Biology
Enzymology
Pharmacology

Background:

Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an enzyme linked to atherosclerosis.
Its role was debated, but evidence now supports a proatherogenic function.

Purpose of the Study:

To review recent developments in selective Lp-PLA(2) inhibition as a therapeutic strategy.
To highlight the role of Lp-PLA(2) in promoting atherosclerotic plaque vulnerability.

Main Methods:

Review of recent animal models and human studies on Lp-PLA(2) inhibitors.
Analysis of Lp-PLA(2) activity, plaque size, and necrotic core area.

Main Results:

Selective Lp-PLA(2) inhibition reduces plasma Lp-PLA(2) activity.
Inhibition also decreases atherosclerotic plaque area and necrotic core size.
Lp-PLA(2) generates lysophosphatidylcholine and oxidized fatty acids, contributing to plaque instability.

Conclusions:

Lp-PLA(2) plays a significant proatherogenic role.
Selective inhibition of Lp-PLA(2) is a promising therapeutic approach for atherosclerosis.
Further research into Lp-PLA(2) inhibitors is warranted.